Countermeasures May Need More Incentives Than Vouchers, Gottlieb Says
Executive Summary
With priority review voucher values falling, Congress may want to think about additional incentives for medical countermeasure development, Commissioner Gottlieb tells Senate committee.
You may also be interested in...
Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials
Researchers find no significant difference in number of rare pediatric disease treatments starting clinical development before or after incentive was created, but advocates aren't ready to give up on the program yet.
Moxidectin Sponsors Credit PRV Program For Enabling River Blindness Approval
Medicines Development for Global Health is the first nonprofit to earn a priority review voucher for bringing a neglected tropical disease therapy to US approval. Project carried on research from the Wyeth era.
Medical Countermeasures: Long-Term Funding Could Spur More Development Work
Chimerix CEO tells Congress allocating Project Bioshield a multi-year funding stream would provide more long-term certainty for countermeasure sponsors.